A discectomy can feel like instant relief until the pain comes back, and the “small” hole in the disc turns into a repeat surgery, degeneration, and lost mobility. Joining the podcast is Greg Lambrecht, founder and executive director of Intrinsic Therapeutics, with host Geoff Pardo to unpack why recurrent lumbar disc herniation is still so common, what surgeons and patients often don’t see downstream, and how his team built Barricaid to address the problem at its source: the annular defect. They also discuss the engineering logic of a bone-anchored barrier and why early “optimal” designs failed inside a body that’s anything but gentle, as well as CMS versus private payer incentives and why trial protocols should be negotiated with reimbursement stakeholders early. Subscribe and leave a review with your biggest question about getting breakthrough devices adopted. LINKS:      Medtech Talk Links:  <a href='https://www.healthtech.com/'>Cambridge Healthtech Institute</a>    <a href='https://medtechconference.com/medtech-talk-podcast/'>Medtech Talk</a>  <a href='https://gildehealthcare.com/'>Gilde Healthcare</a>  Intrinsic Therapeutics Links: <a href='https://barricaid.com/'>Barricaid</a>

A discectomy can feel like instant relief until the pain comes back, and the “small” hole in the disc turns into a repeat surgery, degeneration, and lost mobility. Joining the podcast is Greg Lambrecht, founder and executive director of Intrinsic Therapeutics, with host Geoff Pardo to unpack why recurrent lumbar disc herniation is still so common, what surgeons and patients often don’t see downstream, and how his team built Barricaid to address the problem at its source: the annular defect. They also discuss the engineering logic of a bone-anchored barrier and why early “optimal” designs failed inside a body that’s anything but gentle, as well as CMS versus private payer incentives and why trial protocols should be negotiated with reimbursement stakeholders early. Subscribe and leave a review with your biggest question about getting breakthrough devices adopted. LINKS: Medtech Talk Links: Cambridge Healthtech Institute Medtech Talk Gilde Healthcare Intrinsic Therapeutics Links: Barricaid

A discectomy can feel like instant relief until the pain comes back, and the “small” hole in the disc turns into a repeat surgery, degeneration, and lost mobility. Joining the podcast is Greg Lambrecht, founder and executive director of Intrinsic Therapeutics, with host Geoff Pardo to unpack why recurrent lumbar disc herniation is still so common, what surgeons and patients often don’t see downstream, and how his team built Barricaid to address the problem at its source: the annular defect. They also discuss the engineering logic of a bone-anchored barrier and why early “optimal” designs failed inside a body that’s anything but gentle, as well as CMS versus private payer incentives and why trial protocols should be negotiated with reimbursement stakeholders early.&nbsp;Subscribe and leave a review with your biggest question about getting breakthrough devices adopted.&nbsp;LINKS:&nbsp; &nbsp;&nbsp; &nbsp;Medtech Talk Links:&nbsp; <a href="https://www.healthtech.com/" rel="noopener noreferrer">Cambridge Healthtech Institute</a>&nbsp; &nbsp; <a href="https://medtechconference.com/medtech-talk-podcast/" rel="noopener noreferrer">Medtech Talk</a>&nbsp; <a href="https://gildehealthcare.com/" rel="noopener noreferrer">Gilde Healthcare</a> &nbsp;Intrinsic Therapeutics Links: <a href="https://barricaid.com/" rel="noopener noreferrer">Barricaid</a>&nbsp;

Episode: 205 - Greg Lambrecht on How a Spinal Implant Prevents Repeat Back Surgery

Brian Webster, President and CEO of Kestra Medical Technologies (Nasdaq: KMTS), joins Medtech Talk to discuss his 30-year career in cardiac defibrillation and the road to founding Kestra. With host Swaril Mathur, Webster unpacks learnings from leading through decades of repeated acquisitions, divestitures, and restructurings — and keeping the team motivated through it all. Their conversation explores what it takes to commercialize a rental fleet model with outsourced manufacturing, revenue cycle management, and payer contracts, as well as closing with the decision to IPO and staying steady in volatile markets by focusing on execution fundamentals. Subscribe, share this with a MedTech operator who’s scaling something hard, and leave a rating or review with the leadership lesson that hit you most. Medtech Talk Links:  <a href='https://www.healthtech.com/'>Cambridge Healthtech Institute</a>    <a href='https://medtechconference.com/medtech-talk-podcast/'>Medtech Talk</a>  <a href='https://gildehealthcare.com/'>Gilde Healthcare</a>  MicroTransponderLinks: <a href='https://www.microtransponder.com/'>MicroTransponder</a> Kestra Medical Technologies: <a href='https://kestramedical.com/'>Kestra Medical Technologies</a>

Brian Webster, President and CEO of Kestra Medical Technologies (Nasdaq: KMTS), joins Medtech Talk to discuss his 30-year career in cardiac defibrillation and the road to founding Kestra. With host Swaril Mathur, Webster unpacks learnings from leading through decades of repeated acquisitions, divestitures, and restructurings — and keeping the team motivated through it all. Their conversation explores what it takes to commercialize a rental fleet model with outsourced manufacturing, revenue cycle management, and payer contracts, as well as closing with the decision to IPO and staying steady in volatile markets by focusing on execution fundamentals. Subscribe, share this with a MedTech operator who’s scaling something hard, and leave a rating or review with the leadership lesson that hit you most. Medtech Talk Links: Cambridge Healthtech Institute Medtech Talk Gilde Healthcare MicroTransponderLinks: MicroTransponder Kestra Medical Technologies: Kestra Medical Technologies

Brian Webster, President and CEO of Kestra Medical Technologies (Nasdaq: KMTS), joins Medtech Talk to discuss his 30-year career in cardiac defibrillation and the road to founding Kestra. With host Swaril Mathur, Webster unpacks learnings from leading through decades of repeated acquisitions, divestitures, and restructurings — and keeping the team motivated through it all. Their conversation explores what it takes to commercialize a rental fleet model with outsourced manufacturing, revenue cycle management, and payer contracts, as well as closing with the decision to IPO and staying steady in volatile markets by focusing on execution fundamentals. Subscribe, share this with a MedTech operator who’s scaling something hard, and leave a rating or review with the leadership lesson that hit you most.&nbsp;Medtech Talk Links:&nbsp; <a href="https://www.healthtech.com/" rel="noopener noreferrer">Cambridge Healthtech Institute</a>&nbsp; &nbsp; <a href="https://medtechconference.com/medtech-talk-podcast/" rel="noopener noreferrer">Medtech Talk</a>&nbsp; <a href="https://gildehealthcare.com/" rel="noopener noreferrer">Gilde Healthcare</a> &nbsp;MicroTransponderLinks: <a href="https://www.microtransponder.com/" rel="noopener noreferrer">MicroTransponder</a>&nbsp;Kestra Medical Technologies: <a href="https://kestramedical.com/" rel="noopener noreferrer">Kestra Medical Technologies</a>&nbsp;&nbsp;

Episode: 204 - Brian Webster on Steady Leadership through Turbulent Times

In this month’s Medtech Talk, co-host Swaril Mathur, vice president of business development at Axonics, debuts in her first episode with John Woock, former EVP and chief marketing and strategy officer at Axonics. They discuss the early days of their company, including what motivated Woock to join a company that was considered risky at the time, what he learned from supporting and working directly with the field team, and how Axonics handled the early stages of commercial launch during the pandemic. Woock also reflects on how much the company has changed over the years in its culture and leadership, including the decisions that felt good and the ones that were harder to grapple with. Medtech Talk Links:  <a href='https://www.healthtech.com/'>Cambridge Healthtech Institute</a>    <a href='https://medtechconference.com/medtech-talk-podcast/'>Medtech Talk</a>  <a href='https://gildehealthcare.com/'>Gilde Healthcare</a>   Axonics Links:  <a href='https://www.axonics.com/'>Axonics</a>

In this month’s Medtech Talk, co-host Swaril Mathur, vice president of business development at Axonics, debuts in her first episode with John Woock, former EVP and chief marketing and strategy officer at Axonics. They discuss the early days of their company, including what motivated Woock to join a company that was considered risky at the time, what he learned from supporting and working directly with the field team, and how Axonics handled the early stages of commercial launch during the pandemic. Woock also reflects on how much the company has changed over the years in its culture and leadership, including the decisions that felt good and the ones that were harder to grapple with. Medtech Talk Links: Cambridge Healthtech Institute Medtech Talk Gilde Healthcare Axonics Links: Axonics

In this month’s Medtech Talk, co-host Swaril Mathur, vice president of business development at Axonics, debuts in her first episode with John Woock, former EVP and chief marketing and strategy officer at Axonics. They discuss the early days of their company, including what motivated Woock to join a company that was considered risky at the time, what he learned from supporting and working directly with the field team, and how Axonics handled the early stages of commercial launch during the pandemic. Woock also reflects on how much the company has changed over the years in its culture and leadership, including the decisions that felt good and the ones that were harder to grapple with.&nbsp;Medtech Talk Links:&nbsp; <a href="https://www.healthtech.com/" rel="noopener noreferrer">Cambridge Healthtech Institute</a>&nbsp; &nbsp; <a href="https://medtechconference.com/medtech-talk-podcast/" rel="noopener noreferrer">Medtech Talk</a>&nbsp; <a href="https://gildehealthcare.com/" rel="noopener noreferrer">Gilde Healthcare</a>&nbsp; &nbsp;Axonics Links:&nbsp; <a href="https://www.axonics.com/" rel="noopener noreferrer">Axonics</a>&nbsp;

Episode: 195 - John Woock on Crossing the Chasm from Clinical to Commercial

In his early education Anton Clifford was advised against focusing on both science and economics. But he’s put that education to good use in his entrepreneurial career. With a foundation in engineering, Clifford quickly turned to medical devices. First in his native Ireland and later in the US with Abbott Laboratories, Clifford got firsthand experience with device engineering as well as the challenges of launching new products, divisions, and companies.  On the journey to his current endeavor, Clifford had narrowed his focus to finding an engineering problem with a mechanical component: a massive unmet need with a surgical solution that was under-adopted. As he considered market opportunities, a friend and mentor, Josh Makower, directed him: You’re not trying to make something work; you’re trying to kill ideas.  The last idea standing, so to speak, was an implantable shock absorber, reducing load to the knee joint. After years of development, Moximed has released its FDA study on the most recent product—Misha—with “phenomenal outcomes.” Compared to a surgical alternative, Misha showed superior recovery, pain, function, and no mechanical failures.   Medtech Talk Links:   <a href='https://www.healthtech.com/'>Cambridge Healthtech Institute</a> <a href='https://medtechconference.com/medtech-talk-podcast/'>Medtech Talk</a>  <a href='https://gildehealthcare.com/'>Gilde Healthcare</a>  <a href='https://moximed.com/'>Moximed</a>

In his early education Anton Clifford was advised against focusing on both science and economics. But he’s put that education to good use in his entrepreneurial career. With a foundation in engineering, Clifford quickly turned to medical devices. First in his native Ireland and later in the US with Abbott Laboratories, Clifford got firsthand experience with device engineering as well as the challenges of launching new products, divisions, and companies. On the journey to his current endeavor, Clifford had narrowed his focus to finding an engineering problem with a mechanical component: a massive unmet need with a surgical solution that was under-adopted. As he considered market opportunities, a friend and mentor, Josh Makower, directed him: You’re not trying to make something work; you’re trying to kill ideas. The last idea standing, so to speak, was an implantable shock absorber, reducing load to the knee joint. After years of development, Moximed has released its FDA study on the most recent product—Misha—with “phenomenal outcomes.” Compared to a surgical alternative, Misha showed superior recovery, pain, function, and no mechanical failures. Medtech Talk Links: Cambridge Healthtech Institute Medtech Talk Gilde Healthcare Moximed

In his early education Anton Clifford was advised against focusing on both science and economics. But he’s put that education to good use in his entrepreneurial career. With a foundation in engineering, Clifford quickly turned to medical devices. First in his native Ireland and later in the US with Abbott Laboratories, Clifford got firsthand experience with device engineering as well as the challenges of launching new products, divisions, and companies. &nbsp;On the journey to his current endeavor, Clifford had narrowed his focus to finding an engineering problem with a mechanical component: a massive unmet need with a surgical solution that was under-adopted. As he considered market opportunities, a friend and mentor, Josh Makower, directed him: You’re not trying to make something work; you’re trying to kill ideas. &nbsp;The last idea standing, so to speak, was an implantable shock absorber, reducing load to the knee joint. After years of development, Moximed has released its FDA study on the most recent product—Misha—with “phenomenal outcomes.” Compared to a surgical alternative, Misha showed superior recovery, pain, function, and no mechanical failures. &nbsp; Medtech Talk Links: &nbsp; <a href="https://www.healthtech.com/" rel="noopener noreferrer">Cambridge Healthtech Institute</a> <a href="https://medtechconference.com/medtech-talk-podcast/" rel="noopener noreferrer">Medtech Talk</a>&nbsp; <a href="https://gildehealthcare.com/" rel="noopener noreferrer">Gilde Healthcare</a>&nbsp; <a href="https://moximed.com/" rel="noopener noreferrer">Moximed</a>&nbsp;

Episode: 177 - Launching a New Category of Orthopedics: Moximed’s Journey and Trial Results

With a background as a trauma nurse and experience running clinical research programs, Stacey Pugh brought quite a bit of patient-focused experience with her when she shifted to industry. After several roles in the neurovascular space, now she’s leading the charge at Endogenix, which is using pulsed electric fields to treat Type 2 Diabetes. She and host, Geoff Pardo, talk about a medical officer’s first experience doing sales, the challenges in affecting change management in primary care, funding businesses with SPACs, and more.   Medtech Talk Links:   <a href='https://www.healthtech.com/'>Cambridge Healthtech Institute</a>    <a href='https://medtechconference.com/medtech-talk-podcast/'>Medtech Talk</a>  <a href='https://gildehealthcare.com/'>Gilde Healthcare</a>   <a href='https://www.endogenex.com/'>Endogenex</a>

With a background as a trauma nurse and experience running clinical research programs, Stacey Pugh brought quite a bit of patient-focused experience with her when she shifted to industry. After several roles in the neurovascular space, now she’s leading the charge at Endogenix, which is using pulsed electric fields to treat Type 2 Diabetes. She and host, Geoff Pardo, talk about a medical officer’s first experience doing sales, the challenges in affecting change management in primary care, funding businesses with SPACs, and more. Medtech Talk Links: Cambridge Healthtech Institute Medtech Talk Gilde Healthcare Endogenex

With a background as a trauma nurse and experience running clinical research programs, Stacey Pugh brought quite a bit of patient-focused experience with her when she shifted to industry. After several roles in the neurovascular space, now she’s leading the charge at Endogenix, which is using pulsed electric fields to treat Type 2 Diabetes. She and host, Geoff Pardo, talk about a medical officer’s first experience doing sales, the challenges in affecting change management in primary care, funding businesses with SPACs, and more. &nbsp; Medtech Talk Links: &nbsp; <a href="https://www.healthtech.com/" rel="noopener noreferrer">Cambridge Healthtech Institute</a>&nbsp; &nbsp; <a href="https://medtechconference.com/medtech-talk-podcast/" rel="noopener noreferrer">Medtech Talk</a>&nbsp; <a href="https://gildehealthcare.com/" rel="noopener noreferrer">Gilde Healthcare</a> &nbsp; <a href="https://www.endogenex.com/" rel="noopener noreferrer">Endogenex</a>&nbsp;

Episode: 176 - Stacey Pugh Combines Bedside Background with Market Experience to Affect Change for Type 2 Diabetes

Oxford’s Scott Defelice explains how his company and 3D printing will impact medtech.

What Impact Will 3D Printing Have in Medtech?

Geoff Gurtner, MD, managing partner of TauTona Group, is trying to look differently at how Medtech is created, funded and sold.

Gurtner Explains How TauTona Is Rethinkin Medtech Innovation

Analysts Michael Lachman and Larry Haimovich put down their pens and pick up the mics to discuss the more promising ophthalmology technologies.

Medtech Mic: Lachman, Haimovich Drill Deep into Ophthalmology Devices

Mark Leahey of the MDMA explains how a move against patent troll could cut the legs out from Medtech entrepreneurs and VCs dependent upon IP protection.

MDMA’s Leahey Sees Reasons for Concern and Optimism

Hanson Gifford of The Foundry reviews the evolving challenges behind Medtech innovation and shares details on Fire1 and Ardian.

Foundry’s Gifford: Innovating Innovation in a Changing Health Care World

Matt Hermann, Senior Managing Director of Ascension Ventures, details how Pro-viders and Payer-sponsored investment firms have grown into influential investors in health care.

Ascension’s Hermann Talks State of Payer Provider Venture Groups

Vivo Capital, fresh off raising $750 million for its eight fund, has effectively strad-dled the Pacific, investing in life sciences in US and China. Managing Partner Chen Yu, MD, shares Vivo’s story and explains how US Medtech start-ups stand to benefit from China’s soar-ing health care sector.

Vivo Capital Building Bridges Across Pacific

Justin Klein, MD, general partner at NEA and co-chair of the Medtech Investing Conference, presented NEA’s views the best opportunities in Medtech.

NEA’s Klein Sees Opportunities in Medtech

Dennis Wahr, MD, CEO of Holaira Inc. and co-chair of the Medtech In-vesting Conference, says “the best is yet to come” for Medtech and shares his strategy for successful VC fund raising.

Holaira’s Wahr Sees Success Ahead for Medtech

Intersect ENT CEO Lisa Earnhardt shares her perspective of ENT, the entire Medtech sector and how Intersect is outpacing its tech partners in one critical metric.

Intersect ENT Keeps Pace in Tech Rich Silicon Valley

A weekly conversation with the innovators who will change how health care is delivered.

Share Medtech Talk

Sign up to save your podcasts

Medtech Talk

Medtech Talk episodes

About Medtech Talk

Best of Medtech Talk

More shows like Medtech Talk

All-In with Chamath, Jason, Sacks & Friedberg